Medical technology companies face one more subdued earnings quarter before heading into 2027 with their strongest growth outlook in more than two years, following a punishing stretch of policy uncertainty, cyberattacks and device recalls.
Medical technology companies face one more subdued earnings quarter before heading into 2027 with their strongest growth outlook in more than two years, following a punishing stretch of policy uncertainty, cyberattacks and device recalls.
<iframe src="https://statesidedaily.com/embed/cluster/bfe3f3d2bbd402c02b1560eb759cd1def82a4bc9" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Medtech Faces One More Weak Quarter Before a 2027 Rebound"></iframe>
